Cook Richard, Hendifar Andrew E
P T. 2019 Jul;44(7):424-427.
Carcinoid syndrome causes substantial morbidity and reduces quality of life and survival. In a recent clinical trial, 97% of patients reported bowel movement-related issues, abdominal pain, flushing, and low energy. Combining somatostatin analogs with elotristat ethyl provides a new option for managing refractory CS symptoms. Health care providers should consider strategies that take advantage of approved dosing for patients with CS-related diarrhea.
类癌综合征会导致严重的发病率，并降低生活质量和生存率。在最近的一项临床试验中，97%的患者报告了与排便相关的问题、腹痛、潮红和精力不足。将生长抑素类似物与艾托司他乙酯联合使用为治疗难治性类癌综合征症状提供了一种新选择。医疗保健提供者应考虑利用已批准的剂量策略来治疗类癌综合征相关腹泻患者。
